Compare RAY & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAY | QNRX |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | 6 |
| Industry | Consumer Electronics/Appliances | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 11.6M |
| IPO Year | 2022 | 2023 |
| Metric | RAY | QNRX |
|---|---|---|
| Price | $3.71 | $5.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 18.8K |
| Earning Date | 07-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $5.20 |
| 52 Week High | $5.49 | $41.80 |
| Indicator | RAY | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 33.17 |
| Support Level | $3.24 | N/A |
| Resistance Level | $4.13 | $6.84 |
| Average True Range (ATR) | 0.24 | 0.44 |
| MACD | 0.13 | -0.04 |
| Stochastic Oscillator | 90.36 | 15.96 |
Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.